Cargando…

In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy

Triple negative breast cancer (TNBC) patients exhibit poor survival outcomes and lack effective targeted therapies. Using unbiased in vivo genome-wide CRISPR screening, we interrogated cancer vulnerabilities in TNBC and identified an interplay between oncogenic and tumor suppressor pathways. This st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Meiou, Yan, Gang, Wang, Ni, Daliah, Girija, Edick, Ashlin M., Poulet, Sophie, Boudreault, Julien, Ali, Suhad, Burgos, Sergio A., Lebrun, Jean-Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144221/ https://www.ncbi.nlm.nih.gov/pubmed/34031411 http://dx.doi.org/10.1038/s41467-021-23316-4

Ejemplares similares

Combined in vitro/in vivo genome-wide CRISPR screens in triple negative breast cancer identify cancer stemness regulators in paclitaxel resistance
por: Yan, Gang, et al.
Publicado: (2023)

TGFβ/cyclin D1/Smad-mediated inhibition of BMP4 promotes breast cancer stem cell self-renewal activity
por: Yan, Gang, et al.
Publicado: (2021)

Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis
por: Shams, Anwar, et al.
Publicado: (2021)

Effects of mTOR Inhibitors on Components of the Salvador-Warts-Hippo Pathway
por: Chiang, Jonathan, et al.
Publicado: (2012)

Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition
por: Tian, Jun, et al.
Publicado: (2021)

CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer
por: Dai, Meiou, et al.
Publicado: (2016)

A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion
por: Dai, Meiou, et al.
Publicado: (2012)

Erratum to: A novel function for p21 Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion
por: Dai, Meiou, et al.
Publicado: (2017)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
por: Spormann, Luise, et al.
Publicado: (2020)

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma
por: Kling, Matthew J., et al.
Publicado: (2021)

CPSF6 is a Clinically Relevant Breast Cancer Vulnerability Target: Role of CPSF6 in Breast Cancer
por: Binothman, Najat, et al.
Publicado: (2017)

New insights into the pathophysiology of the tuberous sclerosis complex: Crosstalk of mTOR- and hippo-YAP pathways in cell growth
por: Dill, Patricia E, et al.
Publicado: (2015)

Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration
por: Hachim, Ibrahim Y., et al.
Publicado: (2017)

Author Correction: Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration
por: Hachim, Ibrahim Y., et al.
Publicado: (2022)

Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer
por: Tian, Jun, et al.
Publicado: (2017)

Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
por: Xu, Chenyue, et al.
Publicado: (2022)

Interplay Between mTOR and Hippo Signaling in the Ovary: Clinical Choice Guidance Between Different Gonadotropin Preparations for Better IVF
por: Papageorgiou, Kyriaki, et al.
Publicado: (2021)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
por: Grabinski, Nicole, et al.
Publicado: (2012)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth
por: Soliman, Ghada A, et al.
Publicado: (2020)

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
por: Kim, Hyera, et al.
Publicado: (2020)

Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells
por: Reita, Damien, et al.
Publicado: (2019)

mTOR-dependent signalling in Alzheimer's disease
por: Pei, Jin-Jing, et al.
Publicado: (2008)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

The mTOR–lysosome axis at the centre of ageing
por: Carosi, Julian M., et al.
Publicado: (2021)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Promotion of Ovarian Follicle Growth following mTOR Activation: Synergistic Effects of AKT Stimulators
por: Cheng, Yuan, et al.
Publicado: (2015)

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017)

Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma
por: Sun, Kaiyan, et al.
Publicado: (2023)

Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion
por: Dai, Meiou, et al.
Publicado: (2013)

Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells
por: Tian, Jun, et al.
Publicado: (2018)

Erratum to: Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion
por: Dai, Meiou, et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability
por: Gremke, Niklas, et al.
Publicado: (2020)

Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes
por: Guo, Jimin, et al.
Publicado: (2014)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i7r5c0mef3vf5tpf3c83a0tt6o